These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

555 related items for PubMed ID: 11743503

  • 21. Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease.
    Jain DL, Sarathi V, Desai S, Bhatnagar M, Lodha A.
    Hemoglobin; 2012; 36(4):323-32. PubMed ID: 22734586
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.
    Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, Orringer E, Bellevue R, Olivieri N, Eckman J, Varma M, Ramirez G, Adler B, Smith W, Carlos T, Ataga K, DeCastro L, Bigelow C, Saunthararajah Y, Telfer M, Vichinsky E, Claster S, Shurin S, Bridges K, Waclawiw M, Bonds D, Terrin M.
    JAMA; 2003 Apr 02; 289(13):1645-51. PubMed ID: 12672732
    [Abstract] [Full Text] [Related]

  • 24. Hydroxyurea therapy for diverse pediatric populations with sickle cell disease.
    Rogers ZR.
    Semin Hematol; 1997 Jul 02; 34(3 Suppl 3):42-7. PubMed ID: 9317200
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Splenic complications in pediatric sickle cell disease: A retrospective cohort review.
    George A, Conneely SE, Mangum R, Fasipe T, Lupo PJ, Scheurer ME.
    Pediatr Blood Cancer; 2024 Oct 02; 71(10):e31219. PubMed ID: 39054677
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia.
    Ballas SK, McCarthy WF, Guo N, Brugnara C, Kling G, Bauserman RL, Waclawiw MA.
    Hemoglobin; 2010 Oct 02; 34(5):424-9. PubMed ID: 20854115
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Effect of long-term transfusion on growth in children with sickle cell anemia: results of the STOP trial.
    Wang WC, Morales KH, Scher CD, Styles L, Olivieri N, Adams R, Brambilla D, STOP Investigators.
    J Pediatr; 2005 Aug 02; 147(2):244-7. PubMed ID: 16126058
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
    Italia K, Jain D, Gattani S, Jijina F, Nadkarni A, Sawant P, Nair S, Mohanty D, Ghosh K, Colah R.
    Blood Cells Mol Dis; 2009 Aug 02; 42(1):25-31. PubMed ID: 18954999
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Long-term results using hydroxyurea/phlebotomy for reducing secondary stroke risk in children with sickle cell anemia and iron overload.
    Greenway A, Ware RE, Thornburg CD.
    Am J Hematol; 2011 Apr 02; 86(4):357-61. PubMed ID: 21442640
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Hydroxyurea therapy lowers TCD velocities in children with sickle cell disease.
    Kratovil T, Bulas D, Driscoll MC, Speller-Brown B, McCarter R, Minniti CP.
    Pediatr Blood Cancer; 2006 Dec 02; 47(7):894-900. PubMed ID: 16526051
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.